title: Inhibition of 5alpha-reductase activity in SZ95 sebocytes and HaCaT keratinocytes in vitro.
abstract: Inhibition of 5alpha-reductase type 1 has been considered to be a promising target for treatment of androgen-dependent skin disorders, however, currently published clinical results on acne treatment are rather disappointing. In this study, the influence of selective inhibitors of 5alpha-reductase on testosterone metabolism within SZ95 sebocytes and HaCaT keratinocytes IN VITRO was investigated. In both cell types, the isotype 1 inhibitor MK386 completely inhibited the conversion of testosterone to 5alpha-dihydrotestosterone in concentrations higher than 10 (-9) M. Inhibitors of the isotype 2 such as finasteride, dihydrofinasteride, and turosteride, were >100-fold less active, while, as expected, androgen receptor inhibitors did not affect the 5alpha-reductase activity. MK386, but not finasteride, reduced testosterone-stimulated proliferation and slightly reduced the testosterone-induced increase in the amount of SZ95 sebocyte proteins. The androgen receptor inhibitor cyproterone acetate exhibited no effect on testosterone-induced proliferation, but inhibited the 5alpha-dihydrotestosterone-induced sebocyte proliferation. Our experimental findings and the existing clinical results indicate that the inhibition of 5alpha-reductase activity alone may be insufficient to reduce overall sebocyte activity and improve acne lesions.
authors.affiliation: Division of Dermatology and Cutaneous Sciences, Michigan State University, East Lansing MI, USA.
authors.forename: K
authors.initials: K
authors.lastname: Seiffert
authors.forename: H
authors.initials: H
authors.lastname: Seltmann
authors.forename: M
authors.initials: M
authors.lastname: Fritsch
authors.forename: C C
authors.initials: CC
authors.lastname: Zouboulis
mesh_terms: D059002:Androgen Receptor Antagonists; D000728:Androgens / Q000494:pharmacology; D001378:Azasteroids / Q000494:pharmacology; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D042944:Cholestenone 5 alpha-Reductase / Q000378:metabolism*; D018120:Finasteride / Q000494:pharmacology; D006801:Humans; D015603:Keratinocytes / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D014176:Protein Biosynthesis / Q000187:drug effects; D012627:Sebaceous Glands / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D013739:Testosterone / Q000378:metabolism
chemical_list: C090665:4,7beta-dimethyl-4-azacholestan-3-one; D059002:Androgen Receptor Antagonists; D000728:Androgens; D001378:Azasteroids; D013739:Testosterone; D018120:Finasteride; D042944:Cholestenone 5 alpha-Reductase